Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Cash (2016 - 2025)

Lexaria Bioscience's Change in Cash history spans 11 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 57.07% year-over-year to $2.5 million; the TTM value through Nov 2025 reached -$3.8 million, down 162.0%, while the annual FY2025 figure was -$4.7 million, 191.26% down from the prior year.
  • Change in Cash for Q4 2025 was $2.5 million at Lexaria Bioscience, up from -$2.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $8.8 million in Q1 2021 and bottomed at -$2.8 million in Q3 2025.
  • The 5-year median for Change in Cash is -$1.2 million (2021), against an average of $187794.6.
  • The largest annual shift saw Change in Cash plummeted 195.7% in 2021 before it skyrocketed 3569.34% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$1.2 million in 2021, then dropped by 3.61% to -$1.3 million in 2022, then soared by 147.03% to $602063.0 in 2023, then soared by 162.16% to $1.6 million in 2024, then soared by 57.07% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Change in Cash are $2.5 million (Q4 2025), -$2.8 million (Q3 2025), and -$1.9 million (Q2 2025).